Teligent Inc (NASDAQ:TLGT) CEO Jason Grenfell-Gardner bought 25,000 shares of Teligent stock in a transaction on Thursday, May 23rd. The shares were bought at an average cost of $0.69 per share, with a total value of $17,250.00. Following the acquisition, the chief executive officer now directly owns 119,849 shares in the company, valued at $82,695.81. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of TLGT opened at $0.68 on Friday. The stock has a market cap of $46.73 million, a PE ratio of -2.06 and a beta of 1.45. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 14.43. Teligent Inc has a 12-month low of $0.66 and a 12-month high of $4.52.
Teligent (NASDAQ:TLGT) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.16). The business had revenue of $16.78 million for the quarter, compared to the consensus estimate of $17.73 million. Teligent had a negative net margin of 73.56% and a negative return on equity of 103.41%. On average, equities analysts forecast that Teligent Inc will post -0.17 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC bought a new stake in Teligent in the 4th quarter worth approximately $39,000. Paloma Partners Management Co bought a new stake in Teligent in the 4th quarter worth approximately $40,000. Raymond James & Associates lifted its position in Teligent by 21.9% in the 4th quarter. Raymond James & Associates now owns 36,700 shares of the company’s stock worth $50,000 after buying an additional 6,600 shares during the last quarter. SG Americas Securities LLC bought a new stake in Teligent in the 4th quarter worth approximately $60,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Teligent in the 1st quarter worth approximately $55,000. Hedge funds and other institutional investors own 64.59% of the company’s stock.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Recommended Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.